Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps)

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Cardiology Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Fei Lu
University of Minnesota Medical School
Minneapolis, MN 55455
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps)

Author(s): James A. Reiffel

Affiliation: ECG Laboratory, 6th floor, Milstein Pavilion, The New York Presbyterian Hospital, 177 Fort Washington Ave., New York, NY 10032, USA.

Abstract

Advances in the therapy of atrial fibrillation (AF) have not come easily or quickly, despite the recognized need for significantly better antiarrhythmic agents for AF termination and prevention as well as for more user-friendly anticoagulants for the prevention of emboli in patients with AF. Rather, the road has been only slowly progressive and bumpy. This manuscript will introduce the recent issues with dronedarone, the complex development story for vernakalant, and the appearance of the new oral anticoagulants. Each of these three considerations will then be explored in more depth by the invited experts for this “mini-Thematic issue” in Current Cardiology Reviews.

Keywords: Atrial fibrillation, antiarrhythmic drugs, anticoagulants, dronedarone, vernakalant, factor Xa and direct thrombin inhibitors.

Download Free Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 4
First Page: 295
Last Page: 296
Page Count: 2
DOI: 10.2174/1573403X1004140707121644
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science